ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Outcomes Beyond 10 Years After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Valve Stenosis.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcatheter Aortic Valve Replacement Within a Structured Secondary Prevention Framework in Cardiovascular Disease.Cureus · 2026Review
- Aortic Valve Interventions in Asymptomatic Severe Aortic Stenosis: Who, Why, and When?Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data is available on long-term outcomes and valve durability measures of transcatheter aortic valve implantation (TAVI).
aimsThis study sought to assess clinical and echocardiographic outcomes of high-risk patients during the early experience of TAVI with a follow-up period extending beyond 10 years.
methodsPatients were included who had undergone TAVI at the Heart Center Leipzig between 2006 and 2012. Valve durability measures including moderate and severe structural valve deterioration (SVD) were defined according to the updated standardized definitions of the Valve Academic Research Consortium 3 (VARC-3).
resultsA total of 1825 patients were included. The 12-year mortality rate was 92.8%. At 12 years post-TAVI, the cumulative incidence of SVD was 9.8% in the total population. Complete echocardiographic follow-up at ≥ 9 years was available for 56 patients. The median follow-up of this subgroup was 10.0 years. Moderate SVD was observed in three patients of the echocardiographic follow-up cohort (5.4%) and severe SVD in two patients (3.6%). Self-expanding (SE) transcatheter heart valves (THV) had a significantly lower rate of any SVD (2.8% vs 20.0%, p = 0.030) than balloon-expandable (BE) THV.
conclusionLong-term mortality rates in high-risk patients treated with TAVI more than 10 years ago are substantial, which limits assessment of valve durability measures. In a subgroup of survivors beyond 9 years, the cumulative incidence of SVD was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.